Tehran University of Medical Sciences

Science Communicator Platform

Share By
Cancer Immunotherapy Publisher



Arabpour J ; Davodabadi F ; Nigam M
Authors

Source: Interdisciplinary Biotechnological Advances Published:2025


Abstract

The mortality rate of cancer is ranked second worldwide. The most common treatment options for cancer patients are radiation, chemotherapy, and/or surgery. When these standard therapies are combined on the primary tumor, they are most often effective, but preventing disseminated tumor cells from spreading is usually more challenging. By using cancer immunotherapy, cancer cells disseminated throughout the blood circulation, as well as micro-metastases in distant organs, can be treated. In cancer immunotherapy, antibodies target specific cancers and immune effector mechanisms. Cancer immunotherapy, including its mechanisms, therapeutic agents, and clinical implications, is discussed in this chapter. The challenges associated with next-generation CAR-Ms and personalized vaccines are also discussed. Combining immunotherapy and chemotherapy, radiotherapy, or epigenetic modulators can maximize treatment effectiveness. In conclusion, individualized medicine approaches and ongoing research will impact cancer immunotherapy in the future. © The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2025.
Related Docs
View other Related Docs
1. Tumor Immunology, Clinical Immunology (2022)
2. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
3. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (8)
Seyed Hamidollah Ghaffari (3)
Other Related Docs
4. Tumor-Infiltrating Lymphocyte Therapy for Lung Cancer and Its Future Paradigms, Expert Opinion on Biological Therapy (2022)
5. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
6. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
7. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
8. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
9. Car T Cell Therapy in Solid Tumors; With an Extensive Focus on Obstacles and Strategies to Overcome the Challenges, International Immunopharmacology (2021)
10. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
11. Shedding Light on the Side Effects of Immunotherapies Used for Leukemia: An Updated Review of the Literature, Expert Review of Anticancer Therapy (2023)
12. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
13. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
14. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
15. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
16. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
17. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)
18. The Efficacy and Applicability of Chimeric Antigen Receptor (Car) T Cell-Based Regimens for Primary Bone Tumors: A Comprehensive Review of Current Evidence, Journal of Bone Oncology (2024)
19. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
20. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)